Why Aphria Inc (TSX:APHA) Stock Rose 17% in August

Despite what was a pretty rough month for cannabis stocks, shares in Aphria Inc (TSX:APHA(NYSE:APHA), rose 17% in August. Find out what led to the stocks outperformance in this rapidly growing and exciting market.

Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

Despite what’s been for the most part a rough patch for cannabis stocks, shares in Aphria Inc (TSX:APHA)(NYSE:APHA), Canada’s fourth largest licensed pot producer, rose 17% in August.

So what exactly led to APHA’s outperformance last month?

Let’s take a closer look and find out.

Aphria reported its fourth quarter and fiscal year-end earnings on August 1, and for the most part, the results were fairly encouraging.

Backed by strong growth in adult use, Aphria delivered impressive year-over-year numbers including revenues up 969% and gross profits that nearly doubled.

Growth was encouraging against its most recent third quarter results as well, including 75% net revenue growth and revenues for adult-use cannabis us 158% from the prior quarter.

Once again, the company continues to demonstrate that it can deliver results on a profitable basis as well, reporting net income of $15.8 million in the fourth quarter and adjusted EBITDA of $1.9 million for the quarter.

Those results compare favourably to the net loss of $108 million it had reported in the third quarter — and better than the $5 million in net losses reported in the fourth quarter one year ago.

Meanwhile, Aphria also closed a convertible note offering during the fourth quarter for proceeds of over US$335 million at a rate of 5.25% per year, and now has over $571 million of cash sitting on its books, including marketable investments.

That should set it up well to go after not only an expanding Canadian market, but also a rapidly growing international market for cannabis.

Also, while revenues per gram of cannabis sold did decline in the quarter, the company continues to go after new and untapped markets for the drug, including the announcement of a new CBD-based nutraceutical product line for the German market earlier this year.

With more than 200,000 plants already under cultivation for the current grow season, including the new expanded area of its Aphria One facility, management feels as though its now on track for annual production capacity of as much as 255,000 kilograms of the drug once all is said and done, including having received licenses for all of its facilities.

Foolish bottom line

In light of the fact that Aphria sold just 5,774 kilograms of cannabis during the fourth quarter those forecasted production estimates suggest that there’s still a long road ahead of this company before it truly gets to where it wants to go.

Yet it could prove to be a handsomely rewarding and exciting road for investors — provided management can trim some of its existing operating costs and return itself to the form that it was in when it became the first licensed pot producer to record a quarterly net profit.

Investors interested in the cannabis space will want to continue to watch this exciting company, which, despite a strong showing in August, still trades toward the bottom end of its trailing twelve-month price range.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »